9月22日 - ** Telix Pharmaceuticals（TLX.AX）股价一度上涨6.8%至16.83澳元，创下自9月15日以来的最大盘中涨幅
** 该公司周一股价下跌11.7%，此前 (link)同意以约16.5亿美元（按无现金、无债务基础计算）收购总部位于德国的ITM Isotope Technologies Munich SE
** 不过，花旗认为，ITM的同位素供应业务足以支撑此次前期股权发行和债务融资
** 补充指出，ITM是全球公认的无载体镥供应商，该物质被用于诺华公司的Pluvicto等产品
** 该券商认为，在当前正经历横向和纵向整合的市场环境下，此项交易具有战略意义
** 今年以来，TLX股价上涨46.5%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.